SV

Street Verdict

Analyst Scorecard

THYROCARE · NSE

Thyrocare Technologies Limited

₹528.45

+4.67% (+₹23.6)

Prev. close

₹504.85

Volume

90,96,697

Delivery %

6.8%

As of

20 Nov 2026

Price history

₹528.45-₹79.8 (-13.12%) · 3M
18 Aug 2026 → 20 Nov 2026
50055060018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

1 analyst stance · last 90 days · one per analyst

Trackable

1 · 1 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (1)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 3 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Thyrocare Technologies Limited

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.

Details

Sector

Healthcare

Industry

Diagnostics & Research

CEO

Mr. Rahul Franklin Guha

Headquarters

Navi Mumbai

Employees

1,906

Key stats

Market cap

₹7,886.64 Cr

P/E ratio (TTM)

55.2

Dividend yield

1.93%

EPS (TTM)

₹8.97

Beta (1Y · daily vs NIFTY 50)

0.52

Beta (5Y · monthly vs NIFTY 50)

0.98

Shares float

8.11 Cr

EPS · quarter ended Sept 2026

₹0.96

Financial Performance

01 · Financials

0 Cr250 Cr500 Cr750 Cr1000 Cr₹0%10%20%30%FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

051015₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

0358₹-200%0%200%400%12 Nov 2017 Jun 2111 May 2220 Apr 2316 Aug 2425 Jul 2524 Oct 2523 Jun 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-100%0%100%200%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr250 Cr500 Cr750 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr250 Cr500 Cr750 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-100 Cr0 Cr100 Cr200 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹494.62 Cr₹588.86 Cr₹526.67 Cr₹571.88 Cr₹687.35 Cr₹829.04 Cr
EBITDA
₹183.68 Cr₹264.14 Cr₹129.65 Cr₹146.80 Cr₹205.19 Cr₹272.87 Cr
₹113.14 Cr₹176.14 Cr₹64.49 Cr₹70.76 Cr₹91.51 Cr₹163.04 Cr
Diluted EPS
₹7.12₹11.08₹4.05₹4.47₹5.69₹10.24

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹545.80 Cr₹607.66 Cr₹632.72 Cr₹643.88 Cr₹692.75 Cr₹747.22 Cr
₹8.49 Cr₹20.70 Cr₹23.31 Cr₹42.34 Cr₹24.68 Cr₹50.69 Cr
Stockholders' equity
₹427.28 Cr₹526.57 Cr₹534.30 Cr₹526.77 Cr₹546.75 Cr₹585.50 Cr

Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹116.30 Cr₹266.99 Cr₹129.31 Cr₹167.64 Cr₹179.91 Cr₹213.24 Cr
Investing cash flow
₹-50.23 Cr₹-119.71 Cr₹-38.99 Cr₹-91.29 Cr₹-41.11 Cr₹-23.01 Cr
₹-61.57 Cr₹-146.85 Cr₹-86.18 Cr₹-84.80 Cr₹-130.42 Cr₹-169.59 Cr
Capital expenditure
₹-164.37 Cr₹-212.70 Cr₹-43.65 Cr₹-61.58 Cr₹-33.48 Cr₹-20.88 Cr
End cash position
₹13.20 Cr₹13.63 Cr₹17.77 Cr₹9.32 Cr₹17.68 Cr₹38.32 Cr

Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21–Jun 22(3Q)Sep 22–Sep 23(5Q)Dec 23–Sep 24(4Q)Dec 24–Sep 25(4Q)Dec 25–Dec 25(2Q)Mar 26–Jun 26(2Q)
Promoter71.22%71.18%71.14%71.11%71.06%60.93%60.92%
Public28.78%28.82%28.86%28.89%28.94%39.07%39.08%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Thyrocare Technologies Limited₹7,686.09 Cr₹495.553.813.1327.8%0.09+20.7%-63.5%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

2 indices

THYROCARE

Thyrocare Technologies Share Price today after 5.09% gain

Univest · 3 days ago

THYROCARE

Thyrocare Technologies' (NSE:THYROCARE) Solid Earnings Have Been Accounted For Conservatively

Simply Wall St · 17 days ago